Live News EQUITY L impact Jul 01, 2026, 01:41 PM UTC

Citizens Reiterates Market Outperform on Abivax, Maintains $187 Price Target

Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ: ABVX ) with a Market Outperform and maintains $187 price target.

SQUAWKNEWS Updated Jul 01, 2026, 01:41 PM UTC

Citizens analyst Jason N.

Butler reiterates Abivax (NASDAQ: ABVX ) with a Market Outperform and maintains $187 price target.